We provide customised grading services for your clinical trials. Our fellowship-trained retinologists and certified graders provide grading services for various eye images including:
We employ the use of a 24-hour secure server and computers of high caliber and precision.
Contact us for a discussion
A customised imaging and grading protocol will be developed for your perusal
Administrative preparation before the project commences
Project
commences
Project ends
Provision of standardised image capture protocols customised to the clinical trials’ requirements
Development of study and image grading protocols for clinical studies & clinical trials
Certification of study site ophthalmic photographers
Reception, time-stamping, cataloguing and archival of images
Our group of expert graders are fellowship-trained retinologists and certified graders who are well versed in the grading of FFA, ICGA, OCT, OCTA, CFP and FAF images.
They are supported by a team experienced with the Standard Operating Procedures (SOPs) of the Reading Centre and provides the administrative, IT and maintenance support in the daily operations of the FIRC.
A 24-month multicenter, randomized, double-masked study designed to compare the efficacy and safety profile of ranibizumab, 0.5 mg, and Verteporfin Photodynamic Therapy (vPDT) combination therapy with ranibizumab, 0.5 mg, monotherapy in 322 Asian participants with symptomatic macular PCV confirmed by the Central Reading Center using indocyanine green angiography. The study involved 42 sites in seven countries.
A multicenter, double-masked, primarily indocyanine green angiography-guided trial of 61 Asian patients with symptomatic macular polypoidal choroidal vasculopathy. Patients were randomized to verteporfin photodynamic therapy (PDT) (standard fluence), ranibizumab 0.5 mg, or the combination. The primary endpoint was the proportion of patients with indocyanine green angiography-assessed complete regression of polyps at Month 6. Secondary endpoints included mean change in best-corrected visual acuity at Month 6 and safety. The study involved seven sites from five countries.
Evaluation of Polypoidal Choroidal Vasculopathy Lesions on Indocyanine Green Angiography in the First Year of the EVEREST II Study
JAMA Ophthalmol. 2020 Sep 1;138(9):935-942. doi: 10.1001/jamaophthalmol.2020.2443 PMID: 32672800; PMCID: PMC7366282
BMC Ophthalmol. 2020 Aug 6;20(1):324. doi: 10.1186/s12886-020-01582-y PMID: 32762659
Clin Exp Ophthalmol. 2019 Jul;47(5):614-620. doi: 10.1111/ceo.13464. Epub 2019 Feb 10. vasculopathy PMID: 30652395; PMCID: PMC6767036
Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):889-896. doi: 10.1167/iovs.17-22683 PMID: 29435588
JAMA Ophthalmol. 2017 Nov 1;135(11):1206-1213. doi: 10.1001/jamaophthalmol.2017.4030 PMID: 28983556; PMCID: PMC5710379
Graefes Arch Clin Exp Ophthalmol. 2016 Oct;254(10):1923-1930. doi: 10.1007/s00417-016-3333-y. Epub 2016 May 3 PMID: 27142805; PMCID: PMC5045476
Br J Ophthalmol. 2015 May;99(5):624-8. doi: 10.1136/bjophthalmol-2014-305674. Epub 2015 Mar 10 PMID: 25758601; PMCID: PMC4413842
Retina. 2013 Apr;33(4):686-716. doi: 10.1097/IAE.0b013e3182852446 PMID: 23455233
Retina. 2012 Sep;32(8):1453-64. doi: 10.1097/IAE.0b013e31824f91e8 PMID: 22426346
